Importance of performance status for treatment outcome in advanced pancreatic cancer

Table 1 Influence of performance status on median survival in randomized phase III trials

	Overall Survival (mo)		Reference
	KPS 60-80	KPS 90-100
Gemcitabine + Cisplatin	4.91	10.7	Heinemann et al
Gemcitabine	4.81	6.9
Statistical significance	P = 0.64	P = 0.051
Gemcitabine + 5-FU/FA	3.4	8.5	Riess et al
Gemcitabine	4.9	6.2
Statistical significance	P = 0.62	P = 0.172
Gemcitabine + Capecitabine	5.3	10.1	Herrmann et al
Gemcitabine	7.0	7.5
Statistical significance	P = 0.22	P = 0.024

KPS = Karnofsky performance status,

¹subgroup with poor performance status defined as KPS 70%-80%.